TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12756512

Group type: EXPERIMENTAL
Intervention: 200 mg daidzein twice daily for 10 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10051505

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) therapy
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) therapy with steroid priming
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 101
Study: 8595083

Group type: EXPERIMENTAL
Intervention: Pyridoxine (5 mg/kg body weight/day) for 4 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pyridoxine treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normotensive subjects (control group)
Number of subjects: 20
Study: 1709446

Group type: EXPERIMENTAL
Intervention: Single infusion of gamma globulin (2 g/kg over 10 hours)
Number of subjects: 549

Group type: COMPARATOR
Intervention: Four daily infusions of gamma globulin (400 mg/kg for four consecutive days)
Number of subjects: 549

Group type: COMPARATOR
Intervention: Both groups (single infusion and four daily infusions)
Number of subjects: 549
Study: 7027425

Group type: EXPERIMENTAL
Intervention: 600 mg/d antrafenine
Number of subjects: 42

Group type: COMPARATOR
Intervention: 3 g/d aspirin
Number of subjects: 42
Study: 31210140

Group type: EXPERIMENTAL
Intervention: Pictorial asthma action plan (PAAP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Written asthma action plan (WAAP)
Number of subjects: 60
Study: 27687851

Group type: EXPERIMENTAL
Intervention: Minerva Endometrial Ablation System
Number of subjects: 153

Group type: COMPARATOR
Intervention: Rollerball ablation
Number of subjects: 153
Study: 25721567

Group type: EXPERIMENTAL
Intervention: 1.5 mA anodal tDCS on right parietal cortex (P4)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 1.5 mA anodal tDCS on left dorsolateral (F3)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 1.5 mA anodal tDCS on left parietal (P3)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 24
Study: 23266650

Group type: EXPERIMENTAL
Intervention: Uterine manipulator (RUMI) used in group A
Number of subjects: 110

Group type: COMPARATOR
Intervention: No uterine manipulator used in group B
Number of subjects: 110
Study: 21649457

Group type: EXPERIMENTAL
Intervention: Decaffeinated green tea extract (GTE) 1,500 mg daily for 16 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 19234815

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine, 0.5 microg x kg(‐1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Midazolam, 0.025 mg x kg(‐1)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 15
Study: 16720593

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Statin use (observational cohort)
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Statin use prior to first screening
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Statin use >3 years
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Statin use with >1 defined daily dose
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Statin use with >2 defined daily doses
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Statin non-users
Number of subjects: 788

Group type: COMPARATOR
Intervention: Comparison of GFR between groups
Number of subjects: 788
Study: 15448611

Group type: EXPERIMENTAL
Intervention: 2.5 mg levobupivacaine with 25 microg fentanyl
Number of subjects: 40

Group type: COMPARATOR
Intervention: Half the dose of levobupivacaine and fentanyl (1.25 mg levobupivacaine with 12.5 microg fentanyl)
Number of subjects: 40
Study: 11268266

Group type: EXPERIMENTAL
Intervention: gemfibrozil, 1200 mg/d (n = 1264)
Number of subjects: 2531

Group type: COMPARATOR
Intervention: placebo (n = 1267)
Number of subjects: 2531
Study: 9495299

Group type: EXPERIMENTAL
Intervention: FGF‐I (0.01 mg/kg body weight)
Number of subjects: 20
Study: 11271180

Group type: EXPERIMENTAL
Intervention: Venovenous bypass
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no venovenous bypass)
Number of subjects: 0
Study: 2567793

Group type: EXPERIMENTAL
Intervention: Loxiglumide (oral administration, 800 mg three times daily for 7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loxiglumide (oral administration, 30 min before test meal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 5673963

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 5

Group type: COMPARATOR
Intervention: Anticoagulants
Number of subjects: 5
Study: 107583

Group type: EXPERIMENTAL
Intervention: Continuous sodium fluoride treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent sodium fluoride treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31828528

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula (HFNC)
Number of subjects: 50
Study: 30774322

Group type: EXPERIMENTAL
Intervention: Higher-dose physical activity (180 minutes/week)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Lower-dose physical activity (120 minutes/week)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study: 30431582

Group type: EXPERIMENTAL
Intervention: Gaxilose test (GT)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Hydrogen breath test (HBT)
Number of subjects: 147
Study: 26758747

Group type: EXPERIMENTAL
Intervention: Amoxicillin for 3 days
Number of subjects: 2430

Group type: COMPARATOR
Intervention: Placebo for 3 days
Number of subjects: 2430

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 2430

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2430
Study: 24433249

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBT‐I) consisting of sleep restriction, psychoeducation about sleep, stabilization of the circadian rhythm, and challenging and correcting sleep state misperception, in three to eight sessions.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) consisting of pharmacological and supportive psychosocial treatment.
Number of subjects: 0
Study: 23057482

Group type: EXPERIMENTAL
Intervention: Yamamoto New Scalp Acupuncture (YNSA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard poststroke motor rehabilitation (Control)
Number of subjects: 0
Study: 18668363

Group type: EXPERIMENTAL
Intervention: E-T-CMF (epirubicin-alkylator based adjuvant chemotherapy with paclitaxel)
Number of subjects: 279

Group type: COMPARATOR
Intervention: E-CMF (epirubicin-alkylator based adjuvant chemotherapy without paclitaxel)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Adjuvant hormone therapy
Number of subjects: 279
Study: 17166221

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 4483

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4483

Group type: EXPERIMENTAL
Intervention: Survivors of magnesium sulphate group
Number of subjects: 4483

Group type: COMPARATOR
Intervention: Survivors of placebo group
Number of subjects: 4483
Study: 14989560

Group type: EXPERIMENTAL
Intervention: Granulocyte/macrophage colony stimulating factor (GM-CSF) at a dose of 10 microg/kg for 14 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Granulocyte/macrophage colony stimulating factor (GM-CSF)
Number of subjects: 40
Study: 10752807

Group type: EXPERIMENTAL
Intervention: BB-882 (4 mg loading dose on the first day, followed by 96 mg/24 hrs for up to 120 hrs)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: BB-882
Number of subjects: 152
Study: 8968293

Group type: EXPERIMENTAL
Intervention: Structured educational intervention
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (traditional education methods)
Number of subjects: 52
Study: 1403212

Group type: EXPERIMENTAL
Intervention: One reminder letter offering free influenza immunization without an appointment
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Two sequential reminder letters offering free influenza immunization without an appointment
Number of subjects: 3

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3
Study: 3890666

Group type: EXPERIMENTAL
Intervention: Topical 0.1% dexamethasone drops
Number of subjects: 56

Group type: COMPARATOR
Intervention: Nonsteroid group
Number of subjects: 56
Study: 31396727

Group type: EXPERIMENTAL
Intervention: CTB-001
Number of subjects: 24
Study: 28953447

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance therapy (375 mg/m² every 2 months for 3 years)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 240
Study: 25515624

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) integrity scores for NRCPs
Number of subjects: 15

Group type: COMPARATOR
Intervention: Motivational interviewing (MI) integrity scores for RCPs
Number of subjects: 15
Study: 22922954

Group type: EXPERIMENTAL
Intervention: Print-based materials/pedometer group
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Print-based materials/pedometer plus telephone counseling group
Number of subjects: 287

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 287
Study: 21831969

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87

Group type: COMPARATOR
Intervention: Rituximab and Placebo
Number of subjects: 87
Study: 18794162

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian diathermy (LOD)
Number of subjects: 72
Study: 17188851

Group type: EXPERIMENTAL
Intervention: Generalized regression neural network (GRNN) analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Currently accepted compendial methodology
Number of subjects: 0
Study: 14681342

Group type: EXPERIMENTAL
Intervention: SPP301 5 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: SPP301 >20 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: SPP301 50 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: SPP301 100 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: SPP301 (all doses)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: SPP301 metabolite
Number of subjects: 32
Study: 11694611

Group type: EXPERIMENTAL
Intervention: Multivitamin‐multimineral plus iron
Number of subjects: 150

Group type: COMPARATOR
Intervention: Multivitamin‐multimineral plus placebo
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo plus placebo
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo plus iron
Number of subjects: 150
Study: 9443526

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg i.v. naloxone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8494665

Group type: EXPERIMENTAL
Intervention: Cephradine 500 mg twice daily for 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amoxycillin 250 mg three times daily for 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin 250 mg four times daily for 5 days
Number of subjects: 0
Study: 2952150

Group type: EXPERIMENTAL
Intervention: Sodium meglumine diatrizoate
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Meglumine diatrizoate
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Meglumine iodamide
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Sodium meglumine ioxaglate
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Iopromide
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Metrizamide
Number of subjects: 23

Group type: COMPARATOR
Intervention: 5% glucose
Number of subjects: 23

Group type: COMPARATOR
Intervention: Physiologic saline
Number of subjects: 23
Study: 30161291

Group type: EXPERIMENTAL
Intervention: GSK2618960 (0.6 mg kg–1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GSK2618960 (2.0 mg kg–1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 28419841

Group type: EXPERIMENTAL
Intervention: Buffered 1% lidocaine with 1:100,000 Epi
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nonbuffered 2% lidocaine with 1:100,000 Epi
Number of subjects: 24
Study: 25907945

Group type: EXPERIMENTAL
Intervention: 8 mg/kg celecoxib (group A)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg Sou‐Medrol (group B)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (group C)
Number of subjects: 150
Study: 23107610

Group type: EXPERIMENTAL
Intervention: Maternal posturing during labor
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (no maternal posturing)
Number of subjects: 220
Study: 21715516

Group type: EXPERIMENTAL
Intervention: Adequate-dairy (AD) diet (3.5 daily servings)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-dairy (LD) diet (<0.5 daily servings)
Number of subjects: 40
Study: 19340462

Group type: EXPERIMENTAL
Intervention: Gelatine sponge soaked with a 10 mg morphine hydrochloride solution placed in the iliac region for local opiate therapy.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intraoperatively centrally administered opiates injected into the contralateral gluteus maximus muscle for systemic therapy.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups followed for pain intensity every 2 hours during the first 48 hours and 3 times a day from postoperative days 3-10.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Long-term results at 1, 3, 6, and 12 months postoperatively.
Number of subjects: 20
Study: 16442903

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 639

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 639
Study: 14504943

Group type: EXPERIMENTAL
Intervention: Bovine colostrum (BC) supplementation (60 g day(‐1))
Number of subjects: 34

Group type: COMPARATOR
Intervention: Whey protein (WP) supplementation
Number of subjects: 34
Study: 11430324

Group type: EXPERIMENTAL
Intervention: Lovastatin therapy
Number of subjects: 5742
Study: 9747672

Group type: EXPERIMENTAL
Intervention: Motion automated perimetry
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard visual field tests
Number of subjects: 105
Study: 8150110

Group type: EXPERIMENTAL
Intervention: Recombinant human FSH (150 IU, i.v.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Recombinant human FSH (150 IU, IM)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Recombinant human FSH (150 IU, SC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Recombinant human FSH (150 IU, SC, multiple doses)
Number of subjects: 12
Study: 2852038

Group type: EXPERIMENTAL
Intervention: Mandatory aftercare (contracted to attend four aftercare sessions during the initial 3 months)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Voluntary aftercare (participation at clients' discretion)
Number of subjects: 153

Group type: COMPARATOR
Intervention: No aftercare (dissuaded from attending until fourth month)
Number of subjects: 153
Study: 30086484

Group type: EXPERIMENTAL
Intervention: baru almond-enriched diet
Number of subjects: 46
Study: 27615557

Group type: EXPERIMENTAL
Intervention: High viral load
Number of subjects: 306
Study: 25817472

Group type: EXPERIMENTAL
Intervention: Midwife group (misoprostol treatment)
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Physician group (misoprostol treatment)
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Midwife group
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Physician group
Number of subjects: 1010
Study: 23592533

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided puncture
Number of subjects: 208

Group type: COMPARATOR
Intervention: Palpation-guided puncture
Number of subjects: 208
Study: 21365025

Group type: EXPERIMENTAL
Intervention: DynaBlast and DynaMatrix
Number of subjects: 9
Study: 19108738

Group type: EXPERIMENTAL
Intervention: Haptoglobin phenotype (Hp 1-1, Hp 2-1, Hp 2-2)
Number of subjects: 434
Study: 17031012

Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol 100 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol 400 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol 200 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol
Number of subjects: 24
Study: 12646796

Group type: EXPERIMENTAL
Intervention: Reality condoms
Number of subjects: 38

Group type: COMPARATOR
Intervention: Male latex condoms
Number of subjects: 38
Study: 10676922

Group type: EXPERIMENTAL
Intervention: Limited prednisone treatment followed by WinRho SDF (anti-D) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednisone followed by splenectomy
Number of subjects: 0
Study: 8668663

Group type: EXPERIMENTAL
Intervention: FK506 (tacrolimus)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral dose of FK506
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous dose of FK506
Number of subjects: 10
Study: 1979009

Group type: EXPERIMENTAL
Intervention: Doxacurium 0.037 mg kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doxacurium 0.075 mg kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.075 mg kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.09 mg kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose doxacurium 0.075 mg kg‐1
Number of subjects: 0
Study: 7298681

Group type: EXPERIMENTAL
Intervention: Silver sulphadiazine occlusive dressings
Number of subjects: 64

Group type: COMPARATOR
Intervention: Fucidin gauze compressive dressings
Number of subjects: 64
Study: 31142474

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TOC) monotherapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Adalimumab (ADA) with methotrexate (MTX)
Number of subjects: 66
Study: 28639008

Group type: EXPERIMENTAL
Intervention: Barbed suture
Number of subjects: 170

Group type: COMPARATOR
Intervention: Traditional suture
Number of subjects: 170
Study: 26402769

Group type: EXPERIMENTAL
Intervention: Cognitive scores from AD Assessment Scale‐Cognitive subscale (ADAS‐Cog) in EXPEDITION study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional scores from AD Cooperative Study‐Activities of Daily Living instrumental subscale (ADCS‐iADL) and Functional Activities Questionnaire (FAQ) in EXPEDITION study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive scores from AD Assessment Scale‐Cognitive subscale (ADAS‐Cog) in IDENTITY and ADNI studies
Number of subjects: 0
Study: 23732250

Group type: EXPERIMENTAL
Intervention: Any mailed intervention
Number of subjects: 7106

Group type: COMPARATOR
Intervention: Control group (no mailed intervention)
Number of subjects: 7106
Study: 21642603

Group type: EXPERIMENTAL
Intervention: Diluted 4.2% sodium bicarbonate (50 mL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.9% normal saline (50 mL)
Number of subjects: 20
Study: 19202222

Group type: EXPERIMENTAL
Intervention: Re-treatment with pegylated interferon and ribavirin in group I (relapsers)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Re-treatment with pegylated interferon and ribavirin in group II (non responders, partial responders, breakthrough non responders)
Number of subjects: 29
Study: 17100938

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg on demand
Number of subjects: 4262

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg three times per week
Number of subjects: 4262
Study: 15090126

Group type: EXPERIMENTAL
Intervention: Intervention schools (TEENS study)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study: 12577417

Group type: EXPERIMENTAL
Intervention: Sanwu hypotensive decoction (SWHD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 30
Study: 9764785

Group type: EXPERIMENTAL
Intervention: Vitamin E (800 IU daily) and Vitamin C (1000 mg daily)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 8196374

Group type: EXPERIMENTAL
Intervention: Locally-trained teachers (high similarity/low expertise)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Outside nutrition experts (high expertise/low similarity)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: High communicator similarity/high expertise
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: High similarity/low expertise
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Low similarity/high expertise
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Low similarity/low expertise
Number of subjects: 322

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 322
Study: 3230347

Group type: EXPERIMENTAL
Intervention: Hyaluronidase removal of the cumulus oophorus; N = 40 oocytes
Number of subjects: 13

Group type: COMPARATOR
Intervention: Nontreatment group (control); N = 48 oocytes
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Hyaluronidase removal of the cumulus oophorus in 'no previous fertilization' group
Number of subjects: 13

Group type: COMPARATOR
Intervention: Nontreatment group (control) in 'no previous fertilization' group
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Hyaluronidase removal of the cumulus oophorus in immunologic infertility group
Number of subjects: 13

Group type: COMPARATOR
Intervention: Nontreatment group (control) in immunologic infertility group
Number of subjects: 13
Study: 29650023

Group type: EXPERIMENTAL
Intervention: Multiple-media food advertising
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Food advertising exposure
Number of subjects: 160
Study: 29017990

Group type: EXPERIMENTAL
Intervention: Healthy Beyond Pregnancy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 30
Study: 24266497

Group type: EXPERIMENTAL
Intervention: Insulin pen
Number of subjects: 405

Group type: COMPARATOR
Intervention: Vial-and-syringe
Number of subjects: 405
Study: 23588257

Group type: EXPERIMENTAL
Intervention: Isometric handgrip training 3×/week (n=12)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Isometric handgrip training 5×/week (n=11)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (0×/week, n=9)
Number of subjects: 32